Redcare Pharmacy's July Slowdown Tests Investor Patience Despite Record Margins
Published on 08/05/2026 at 06:32 | Redaktion boerse-global.de
The disconnect between Redcare Pharmacy's operational performance and its share price has rarely been wider. The online pharmacy just posted its strongest profitability in a decade, yet investors responded by heading for the exits.
Shares closed Tuesday at €63.55, down 8.10 percent on the week. The stock now sits nearly 39 percent below its 52-week high of €103.60, reached exactly one year ago. The selloff comes despite a half-year report that, on the surface, reads like a growth story firing on all cylinders.
The Numbers Tell One Story
Second-quarter revenue climbed 20 percent to €853 million, propelled by the German prescription business, which surged 58 percent as patients increasingly adopted the digital CardLink system for electronic prescriptions. Adjusted EBITDA jumped 63 percent to €29.6 million, pushing the margin to 3.5 percent — the highest level in ten years. Efficiency gains across international logistics and economies of scale are clearly feeding through to the bottom line. For the first half, revenue totalled roughly €1.7 billion.
While Redcare's efficiency gains are driving its bottom line, many UK businesses are still leaving themselves exposed when it comes to workplace safety documentation. A free toolkit with 41 ready-to-use templates and checklists helps you manage risk assessments effectively and stay compliant. Download the free Risk Assessment Toolkit
The Guidance Tells Another
But management's cautious tone on the outlook has spooked the market. July growth has already slipped below the 20 percent threshold, and the company is bracing for a seasonally softer third quarter. The cooling is most pronounced in Germany's non-prescription segment, where near-term growth is expected to fall under 10 percent — a development market participants largely attribute to normalisation after a strong first half.
For a growth company, the optics of decelerating momentum are hard to ignore, even when the underlying fundamentals remain solid. Some investors clearly decided the time was right to lock in gains.
Analysts Look Past the Soft Patch
The sell-side remains broadly constructive despite the near-term headwinds. The consensus price target across nine analysts sits at €86, implying roughly 35 percent upside from current levels. For the full year, analysts project revenue of approximately €3.41 billion, with per-share losses expected to narrow by around 70 percent to roughly €0.60 — a marked improvement over earlier estimates.
The stock's elevated EBITDA multiple suggests the market is already pricing in a long-term leadership position in European e-pharmacy, even as seasonal swings and the transition to new technical standards for electronic prescriptions inject uncertainty into the second half.
Berlin Looms Large
August brings a potentially pivotal regulatory moment: the finalisation of Germany's pharmacy reform legislation. The package is expected to provide online pharmacies with greater legal certainty and clarify the separation of logistics from pharmaceutical duties — a development that could serve as a medium-term catalyst for the stock.
The regulatory tailwinds are already building. The fixed dispensing fee for prescription medications was raised to €9.00 in July, with a further increase to €9.50 slated for early 2027. That gives online providers like Redcare a more predictable foundation for margin-rich prescription growth.
Adding to the pipeline of technical upgrades, the company is preparing to transition to the "Proof of Patient Presence" standard, or PoPP, scheduled for introduction at the end of 2026. The new protocol aims to enhance security when patients redeem prescriptions via electronic health cards, following the CardLink interface that drove the 58 percent surge in German prescription revenue during the first half.
Just as Redcare is preparing for new regulatory standards, UK employers face their own compliance obligations under the Health & Safety at Work Act. A free toolkit with 9 practical tools — including risk assessments and checklists — helps you meet your legal duties and protect your workforce. Get the free Health & Safety at Work Act Toolkit
Whether the August reform package delivers the regulatory clarity the market is hoping for will likely determine whether this long-term bet holds up — or whether the current bout of profit-taking has further to run.
